KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $5.0 million.

  • Nektar Therapeutics' Other Non-Current Liabilities fell 2730.03% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 2730.03%. This contributed to the annual value of $7.2 million for FY2024, which is 5622.44% up from last year.
  • Per Nektar Therapeutics' latest filing, its Other Non-Current Liabilities stood at $5.0 million for Q3 2025, which was down 2730.03% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Other Non-Current Liabilities registered a high of $27.7 million during Q4 2021, and its lowest value of $2.1 million during Q2 2022.
  • Its 5-year average for Other Non-Current Liabilities is $7.7 million, with a median of $5.6 million in 2025.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 54986.33% in 2021, then crashed by 8572.03% in 2022.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Other Non-Current Liabilities stood at $27.7 million in 2021, then tumbled by 72.77% to $7.6 million in 2022, then tumbled by 38.62% to $4.6 million in 2023, then skyrocketed by 56.22% to $7.2 million in 2024, then plummeted by 30.6% to $5.0 million in 2025.
  • Its Other Non-Current Liabilities was $5.0 million in Q3 2025, compared to $5.6 million in Q2 2025 and $6.8 million in Q1 2025.